The pharmaceutical wholesale industry is facing unprecedented challenges. Tariffs, IRA pricing reforms, and new drug legislation are disrupting supply chains, squeezing margins, and forcing wholesalers to rethink their strategies.
What’s at Risk?
- Tariffs may drive up costs on APIs, packaging, and medical devices.
- IRA-driven pricing shifts could reduce reimbursement rates and impact profitability.
- Supply chain vulnerabilities require new sourcing strategies to ensure product availability.
The pharmaceutical landscape is evolving, and those who act now will define the future. Get in-depth insights into how wholesalers can thrive amid market disruptions.
Download the Report
Alvarez & Marsal Invests in Life Sciences, Adds Eduardo Schur to Lead Business
September 23, 2026
Mr. Schur joins A&M to accelerate the growth of its Life Sciences Strategic Business Unit as companies face rising pressure across clinical development, product launches, and market access.
Alvarez & Marsal Invests in Life Sciences, Adds Eduardo Schur to Lead Business
September 23, 2026
Mr. Schur joins A&M to accelerate the growth of its Life Sciences Strategic Business Unit as companies face rising pressure across clinical development, product launches, and market access.
Alvarez & Marsal Invests in Life Sciences, Adds Eduardo Schur to Lead Business
September 23, 2026
Mr. Schur joins A&M to accelerate the growth of its Life Sciences Strategic Business Unit as companies face rising pressure across clinical development, product launches, and market access.
Alvarez & Marsal Invests in Life Sciences, Adds Eduardo Schur to Lead Business
September 23, 2026
Mr. Schur joins A&M to accelerate the growth of its Life Sciences Strategic Business Unit as companies face rising pressure across clinical development, product launches, and market access.